Lgr5, which is a somatic stem cell biomarker, plays an important role during the
carcinogenesis and tumor progression. But in gastric cancer, the functions of Lgr5 still remain
controversial. Our meta-analysis is performed to evaluate the potential associations between
Lgr5 and the outcome of patients with gastric cancer (GC). In our study, a total of 6 studies
comprising 1092 patients were included. Our results demonstrated that high expression of Lgr5
was not associated to the depth of tumor invasion (pooled OR=1.395, CI95%=0.652-2.958,
P=0.392, random-effect), gender of patients (pooled OR=1.264, 95%CI=0.933-1.713, P=0.13,
fixed effect), tumor distance metastasis (pooled OR=1.1, 95%CI=0.734-3.754, P=0.772,
random-effect), tumor size (pooled OR=0.977, 95%CI=0.705-1.353, P=0.887, random-effect),
TNM stages (pooled OR=1.304, 95%CI=0.449-3.789, p=0.625, random-effect) and lymph node
metastasis (pooled OR=1.507, 95%CI=0.829-2.738, P=0.178, random-effect). But interestingly,
the expression of Lgr5 was associated with the age of GC patients (pooled OR=1.731,
95%CI=1.082-2.769, P=0.02) and Lauren type of GC (OR=2.284, 95%CI=1.611-3.238,
P<0.001). Our findings indicated that Lgr5 might contribute to the intestinal metaplasia during gastric carcinogenesis.
This difference in pathological Lauren’s classification is of practical significance for us to make about appropriate
treatment options in gastric cancer.